secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2025-02-25T23:59:59+00:00
Accession:  0001437749-25-004971
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity initiates new Phase 2 protocol for stenoparib in advanced ovarian cancer
--------------------------------------------------------------------------------

- Patient enrollment begins at US sites with new drug product delivered for new Phase 2 protocol.
- Two patients in ongoing phase 2 remain on stenoparib for over 17 months without progression.
- Protocol incorporates FDA feedback and IRB approval; critical data expected by end of summer 2026 for pivotal trial.
- Trial will evaluate stenoparib-DRP companion diagnostic alongside drug for dual regulatory submission.
- Targets $9B+ PARP inhibitor market and addresses FDA Project Optimus dose-finding guidance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000143774925004971/0001437749-25-004971-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000143774925004971/allr20250224_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-004971

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer